Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|93|3|215-219

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.3, 2013-03, pp. : 215-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER-Targeted Tyrosine-Kinase Inhibitors

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 6-16

Karger

Access to resources Recommend Favorite

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Playing Russian Roulette With Tyrosine Kinase Inhibitors

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. : 242-244

John Wiley & Sons Inc

Access to resources Recommend Favorite

Uterine metastasis of lung adenocarcinoma under molecular target therapy with epidermal growth factor receptor tyrosine kinase inhibitors: A case report and review of the literature

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 44, Iss. 2, 2018-02 ,pp. : 352-358

John Wiley & Sons Inc

Access to resources Recommend Favorite

Heart Failure as First Sign of Development of Cardiac Metastases in a Patient with Diagnosis of Papillary Thyroid Carcinoma on Treatment with Tyrosine-Kinase Inhibitors: Differential Diagnoses and Clinical Management

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-08 ,pp. : 591-599

Karger

Access to resources Recommend Favorite